All In Biotech

Drug Trial Radar · NCT07298434

Study of VYD2311 for the Prevention of COVID-19

A Phase 3, Randomized, Triple-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VYD2311 for the Prevention of COVID-19 in Adults and Adolescents

Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,770 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,770

Planned (sponsor's estimate)

Start

Jan 8, 2026

Primary completion

Aug 2026

Study completion Aug 2026

Sponsor

Lead sponsor
Invivyd, Inc.Industry
Sponsor type
Industry
First posted
Dec 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 100 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to test an investigational drug known as VYD2311, which is being developed to lower the risk of getting COVID-19. VYD2311 is a monoclonal antibody that attaches to the virus that causes COVID-19 and helps block it from entering your cells. It is being tested in adults and adolescents at least 12 years old. Participants in this study will be given a "study drug" that will be either VYD2311 or placebo. The study drug will be given as a shot into the muscle in the participant's upper thigh or upper arm once a month with a total of 3 shots during the study. This study will help researchers see how well VYD2311 works to prevent COVID-19 during the 90 days after the first shot. The study will also look at the safety and tolerability of VYD2311, how the study drug is processed by the body (pharmacokinetics), how the immune system reacts to the study drug (immunogenicity), and how well VYD2311 can block the virus from infecting cells (neutralization). To do these tests, your blood will be drawn at certain times during the study.

Conditions

  • COVID-19

Interventions

  • VYD2311-SDDrug

    VYD2311-SD (single-dose arm): Intramuscular injection dosing on Day 1 with VYD2311 and Intramuscular injection dosing Placebo (normal saline) on Day 30 and Day 60

  • VYD2311-MDDrug

    VYD2311-MD (multi-dose): Intramuscular injection dosing on Day 1, Day 30, and Day 60 with VYD2311

  • PlaceboDrug

    Intramuscular injection dosing on Day 1, Day 30, and Day 60 with Placebo (Normal Saline)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RT-PCR-confirmed symptomatic COVID-19 through Day 90Time frame: 90 days

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Invivyd Investigative Site

    Long Beach, California

  • Inviviyd Investigative Site

    San Diego, California

  • Invivyd Investigative Site

    Orlando, Florida

  • Invivyd Investigative Site

    Hinesville, Georgia

  • Invivyd Investigative Site

    Melrose Park, Illinois

  • Invivyd Investigative Site

    Lenexa, Kansas

  • Invivyd Investigative Site

    Silver Spring, Maryland

  • Invivyd Investigative Site

    Burlington, Massachusetts

  • Invivyd Investigative Site

    Southfield, Michigan

  • Invivyd Investigative Site

    Maplewood, Minnesota

  • Invivyd Investigative Site

    Independence, Missouri

  • Invivyd Investigative Site

    Jersey City, New Jersey

  • Invivyd Investigative Site

    The Bronx, New York

  • Invivyd Investigative Site

    Philadelphia, Pennsylvania

  • Invivyd Investigative Site

    Myrtle Beach, South Carolina

  • Invivyd Investigative Site

    Goodlettsville, Tennessee

  • Invivyd Investigative Site

    Houston, Texas

  • Invivyd Investigative Site

    Houston-2, Texas

  • Invivyd Investigative Site

    Irving, Texas

  • Invivyd Investigative Site

    Sugar Land, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.